Loading...

Cardiovascular safety of linagliptin compared to other oral glucose lowering agents in patients with type 2 diabetes: a sequential monitoring program in routine care

BACKGROUND: There are limited real-world data on the comparative cardiovascular (CV) safety of linagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) available since May 2011. OBJECTIVES: We aimed to evaluate the safety of linagliptin vs. other glucose-lowering medications in a multi-year monitori...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Obes Metab
Main Authors: Patorno, E, Gopalakrishnan, C, Brodovicz, KG, Meyers, A, Bartels, DB, Liu, J, Kulldorff, M, Schneeweiss, S
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6785989/
https://ncbi.nlm.nih.gov/pubmed/30941884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13735
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!